Pharvaris to Participate in BioCapital Europe
ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.
Participation Details:
Title: “Shaping the New Biotech Reality – Key Lessons from COVID” Panel Presentation
Date/Time: March 10, 2021, 18:30 CET (12:30 p.m. EST)
Title: Pharvaris Corporate Presentation
Date/Time: March 11, 2021, 14:50 CET (8:50 a.m. EST)
The virtual presentation will be available for 30 days on the Pharvaris website at .
About Pharvaris
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit .
Investor Contact
Chad Rubin, Solebury Trout
Media Contact
Maggie Beller, Russo Partners, LLC
